Obsidian Security Unveils AI Agent Defense to Secure SaaS Data Access
23.9.2025 15:00:00 CEST | Business Wire | Press Release
Obsidian Security, leader in SaaS security, today announced the launch of SaaS AI agent defense, giving enterprises the first purpose-built solution to govern how AI agents access data in SaaS environments. With SaaS now one of the most targeted layers of the enterprise stack, Obsidian is closing the enterprise AI agent-to-SaaS blindspot, where unmanaged agentic AI integrations and excessive privileges can create cascading risk.
In the recent Salesforce attack (UNC6040), threat actors used voice phishing campaigns to obtain initial access and run bulk API queries for large-scale data theft and extortion. The Salesloft Salesforce supply chain breach (UNC6395) illustrated the fragility of SaaS-to-SaaS integrations where one compromised chatbot integration expanded into unauthorized access across Salesforce and downstream applications, including Google Workspace, Slack, Amazon S3, Microsoft Azure and other services at hundreds of enterprises. These attacks underscore the growing pattern of data exfiltration through SaaS integrations.
The rise of AI agents and its rapid pace of adoption further escalates the SaaS security challenge. Low-code and no-code platforms like Microsoft Copilot Studio, ChatGPT Enterprise, Salesforce Agentforce and n8n let any employee build and deploy agents that act inside SaaS applications, chaining tasks, querying data, and executing decisions autonomously without oversight. These agents often carry broad privileges, long-lasting tokens and move sensitive business data at machine speed. If compromised, they can rapidly leak data, escalate access and move laterally across connected SaaS applications, causing widespread damage.
“The AI agent shift is well underway, and we’re seeing the risks firsthand as we help our customers scale adoption securely,” said Hasan Imam, CEO at Obsidian. “87% of enterprises have Microsoft Copilot enabled, more than half the agents access sensitive data, 90% are over-permissioned, and move 16 times more data than humans accessing SaaS applications. These risks are not theoretical, they’re active risks inside enterprises today, often without their awareness.”
Traditional security tools lack visibility into machine-driven activity, cannot contextualize underlying privileges and are unable to enforce controls at the speed and scale of autonomous agents.
“The difference between a major intrusion and successful containment comes down to speed,” said Sunil Seshadri, EVP and CSO at HealthEquity and ex-CISO at Wells Fargo, Visa and NYSE. “Most security teams already struggle to react to incidents fast enough and AI agents raise the stakes even higher. They can trigger workflows across multiple SaaS apps in seconds, often without anyone noticing until damage is done. Obsidian flips that dynamic by detecting issues in near real-time, faster than most security tools are able to, giving teams the chance to shut them down before they spiral out of control.” As a board member of Obsidian Security, Sunil provides strategic guidance in building the industry-leading SaaS and AI Agent Security for Global 2000.
Protecting SaaS Environments from AI Agent Risks
Obsidian is uniquely positioned to address the security risks created by autonomous AI agents in SaaS environments. At its core is the industry’s most comprehensive SaaS threat dataset repository – over 500 curated real-world threat intelligence, enriched with browser-based activity capture and deep SaaS and AI integrations. This intelligence powers the Obsidian Knowledge Graph, a continuously learning model that unifies user and agent activity, identity privileges, and workflows across SaaS and SaaS managed agentic AI platforms into a single correlated view. This live map gives security teams real-time visibility and context to govern agentic AI usage and stop unauthorized agents and behavior inside SaaS environments, where risks emerge and propagate.
“In customer deployments, our continuously learning Knowledge Graph revealed that AI agents in SaaS environments were typically granted ten times more permissions than needed when mapped against real user privileges and entitlements – visibility only Obsidian can deliver,” said Khanh Tran, Chief Product Officer at Obsidian. “By connecting popular AI platforms like Microsoft Copilot Studio, n8n, Salesforce Agentforce, and ChatGPT Enterprise with the Obsidian Knowledge Graph, security teams can finally see what agents are doing in SaaS. That intel means they can stop risks before they spread and empower users to innovate faster without sacrificing security or governance."
This product release is a major step forward in enabling enterprises securely scale AI agent development. Key capabilities in the latest release include:
- Unmatched Visibility & Access Cleanup: Get a live inventory of every AI agent, including its privileges, SaaS connections, and actions, to eliminate excessive or risky access and enable full lifecycle oversight.
- Continuous Observability & Compliance: Map AI agent access across SaaS and trace it to the data touched, with correlated audit trails that link entitlements directly to actions.
- Prevent Misuse & Privilege Escalation: Detect and block agents attempting to exploit trust chains, misuse access, or escalate privileges before damage cascades across SaaS environments.
Current integrations to AI platforms include Microsoft Copilot Studio, ChatGPT Enterprise, Salesforce Agentforce and n8n, with more underway.
To help enterprises quickly understand and assess their exposure, Obsidian is offering a free assessment to its SaaS AI agent defense capabilities for 30 days. For more information and to sign up, visit www.obsidiansecurity.com
Additional Resources
- Learn more about our latest capabilities
- Read the launch blog for deeper coverage
- Watch a demo
- Follow us: X | LinkedIn
About Obsidian Security
Obsidian Security is the leading SaaS security platform, trusted by global enterprises like Snowflake, T-Mobile, and S&P Global. We protect over 250 global organizations, including many of the world’s largest Fortune 1000 and Global 2000 companies, with data center availability in North America, EMEA, and APAC—Saudi Arabia coming soon. Backed by top investors including Greylock, Norwest Venture Partners, and IVP, we’re closing a critical gap: securing the SaaS and AI tools that organizations rely on. Our platform reduces risk, detects and responds to threats, and prevents breaches at the source. Obsidian was built by leaders who redefined endpoint and identity security at CrowdStrike, Okta, Cylance, and Carbon Black.
For more information, visit www.obsidiansecurity.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250923529562/en/
Contacts
press@obsidiansecurity.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom